Quick Facts

• Therapeutic Domain: Cardiovascular Health
• Key Indication: Supports the management of high blood pressure (hypertension).
• Secondary Indication: Helps in the long-term prevention of episodes of chronic stable chest discomfort (angina pectoris).

---

What Nifelat Retard Treats: Main Uses and Benefits

Nifelat Retard (which contains the active ingredient nifedipine) is a prescription medication utilized in the management of specific cardiovascular conditions. The principal applications of this extended-release formulation focus on promoting healthy blood pressure levels and assisting in the control of certain types of chest discomfort.

Supporting Blood Pressure Management

This medication is indicated for the treatment of hypertension (high blood pressure). Consistent use, as prescribed by a healthcare professional, assists in lowering blood pressure. Maintaining target blood pressure levels is important for supporting overall cardiovascular function and is associated with a reduced risk of serious outcomes like stroke or heart conditions.

Addressing Chest Discomfort

Nifelat Retard is also approved for the long-term management of chronic stable angina pectoris. This is a type of chest pain or discomfort that may occur due to reduced blood flow to the heart muscle. The medication helps to decrease the frequency of these discomfort episodes, thereby supporting a patient's capacity for daily activities.

The application of this medication is centered on its recognized use in treating hypertension and chronic stable angina within these specific clinical contexts.

Regulatory References

1. EMA therapeutic overview

Eligibility Profile: Who Can and Cannot Use Nifelat Retard

Regulatory information strictly defines who may be prescribed Nifelat Retard (a modified-release nifedipine formulation).

Contraindicated Populations (Must NOT Use):

• Patients with known hypersensitivity to nifedipine or other dihydropyridines.
• Patients experiencing cardiogenic shock, unstable angina, or within one month of a myocardial infarction.
• Individuals with gastrointestinal obstruction, oesophageal obstruction, or a Kock pouch (due to the modified-release formulation).
• Patients concurrently taking the antibiotic rifampicin.
• Pregnancy (in some stages or unless strictly required for severe conditions) and breastfeeding women.

Restricted or Conditional Use:

Use requires special medical supervision and caution for: patients with impaired liver function, those with manifest heart failure, and patients experiencing severe hypotension (very low blood pressure).

Age and Other Restrictions:

• Children and adolescents under 18 should not use this medicine, as safety and efficacy have not been established.
• No dose adjustment is typically required for older adults based on pharmacokinetics, but careful monitoring is advised.

Interactions with other medicines and products

This section outlines interactions with Nifelat Retard (nifedipine) that are formally documented in official regulatory labeling.

---

Contraindicated Combinations

Co-administration with rifampin is formally contraindicated due to the risk of significant reduction in Nifedipine plasma concentrations and subsequent loss of therapeutic effect. The use of other strong CYP3A4 inducers is also restricted for the same reason.

---

Pharmacokinetic Interactions

Nifedipine is extensively metabolized primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme, which governs most pharmacokinetic interaction patterns. Co-administration with strong CYP3A4 inhibitors, such as certain macrolide antibiotics (e.g., erythromycin) and azole antimycotics (e.g., ketoconazole), increases Nifedipine's systemic exposure (AUC and Cmax). Conversely, co-administration with enzyme inducers (e.g., certain antiepileptic medicines) reduces exposure.

---

Pharmacodynamic and Substance Restrictions

Concurrent use with beta-blockers and other antihypertensive agents may produce an additive hypotensive effect. Furthermore, the consumption of grapefruit juice is strictly prohibited as it significantly increases Nifedipine plasma levels by inhibiting CYP3A4-related metabolism. The herbal product St John’s Wort is also restricted due to its action as a potent enzyme inducer. Caution is advised when administering Nifedipine to patients with documented hepatic impairment, as clearance is decreased, heightening the risk of systemic exposure and interaction effects.

Targeting the L-type Calcium Channels

Nifedipine, the active ingredient, selectively functions as a blocker of the L-type Voltage-Dependent Calcium Channels (L-VDCCs) embedded within the membranes of vascular smooth muscle cells. This action prevents the influx of extracellular calcium ions ( Ca^2+) into the cell cytoplasm. The drug preferentially binds to these channels when they are in an inactivated state, intensifying its blocking action in areas of higher vascular tone.

---

Modulation of Vascular Tone and Systemic Resistance

By limiting intracellular Ca^2+ availability, the mechanism interrupts the excitation-contraction coupling pathway, specifically by suppressing the activity of myosin light-chain kinase (MLCK). This biochemical cascade leads to the relaxation of vascular smooth muscle, resulting in widespread vasodilation (artery widening). This physiological consequence reduces the Systemic Vascular Resistance (SVR), or afterload, against which the heart must pump blood, and concurrently increases blood flow to the heart muscle itself.

---

The Role of Sustained-Release

The specific sustained-release ("Retard") formulation governs the rate of onset for this mechanism, ensuring a slow, continuous blockade of L-VDCCs. This gradual physiological effect is key to minimizing the body's compensatory response known as the baroreceptor reflex, which could otherwise trigger a rapid increase in heart rate. The controlled delivery ensures the modulation of vascular tone remains consistent over time.

Official Administration Guidelines

Nifelat Retard is a prolonged-release tablet formulated for oral administration, designed to deliver the active ingredient over an extended period. The administration protocol is designed to preserve the tablet's controlled-release integrity and ensure appropriate daily exposure.

Usage Component	Standard Instructions
Route & Frequency	The tablet is taken once daily (q.d.) for 24-hour extended-release.
Standard Dosing	Starting doses are generally 30 mg or 60 mg once daily, with the maximum dose typically ranging from 90 mg to 120 mg once daily, depending on the specific formulation and regimen. Doses may be increased gradually, often at 7- to 14-day intervals.
Handling Rule	Tablets must be swallowed whole with liquid and must not be split, crushed, or chewed, as this would disrupt the sustained-release mechanism. Patients may notice the empty tablet shell passing in the stool, which is expected.
Intake Condition	The tablet should be taken at the same time each day. It is advised to avoid consuming grapefruit or grapefruit juice due to potential effects on drug exposure.

Population-Specific Use and Discontinuation

For patients with hepatic impairment, careful monitoring is required, and a lower starting dose may be necessary. Safety and effectiveness are not established for use in children under 18 years of age. If treatment must be discontinued, the dosage should be gradually decreased (tapered) rather than stopped abruptly.

Research evidence / Overview of studies for Nifelat Retard

Evidence for Use in High Blood Pressure Management

The research base for Nifelat Retard (Nifedipine extended-release) includes studies that examined the medication for its role in high blood pressure, known as hypertension. This body of evidence includes numerous Randomized Controlled Trials (RCTs) and systematic reviews that combined data from many different studies. These high-level research designs are the type of evidence often used in medical reviews.

Studies explored outcomes related to systemic imbalance, specifically monitoring changes in the top (systolic) and bottom (diastolic) blood pressure readings. Research also examined the rates of patients reaching a blood pressure goal. Long-term prospective outcome trials, lasting several years, were studied. These long-term studies monitored outcomes related to major cardiovascular events, such as non-fatal stroke, non-fatal myocardial infarction, and death from cardiovascular cause. Research describes the patterns of event incidence observed across different treatment groups. Furthermore, studies examined vascular endpoints, which are outcomes related to blood vessel health, such as changes in heart muscle wall thickness.

Evidence for Use in Chronic Stable Angina Pectoris

The extended-release formulation was also evaluated in research exploring the long-term management of chronic stable chest discomfort (angina pectoris). This research base includes controlled clinical trials and meta-analyses. The studies were designed to assess short-term or episodic symptom patterns associated with effort.

In these trials, researchers primarily monitored patient-reported outcomes describing perceived discomfort, specifically tracking changes in the frequency of angina episodes reported over defined time intervals. They also measured exercise tolerance, which is an outcome reflecting daily functioning or activity level. Findings described the symptom patterns observed in the populations during the short-term study period. Research provides insight into the symptom patterns for patients with this condition, which is characterized by fluctuating or episodic manifestations.

Long-Term Studies and Follow-Up Duration

The evidence base for Nifelat Retard includes studies with varying follow-up durations. For the study of high blood pressure, some long-term outcome trials were conducted, monitoring patients for multiple years to observe the occurrence of major cardiovascular events.

However, research exploring changes in episodic symptoms related to chronic chest discomfort was often based on shorter follow-up durations, sometimes lasting only a few weeks. These studies contribute to understanding short-term changes. Findings for the sustained measurement of symptoms over periods of years are not as fully established as the data for long-term cardiovascular outcomes in blood pressure studies.

Evidence in Specific Patient Populations

Clinical research includes evaluation of Nifelat Retard in different patient groups. Studies monitored outcomes in older adults with hypertension, which contributes to understanding how patients reported their experience in this specific age cohort. Research also examined populations with comorbidities, such as patients with concurrent diabetes mellitus or chronic kidney disease. Findings describe group patterns related to blood pressure measurements within these specific patient groups.

Data for certain groups remain insufficient. For example, research has not yet established evidence for use in the pediatric population. Additionally, evidence exploring the drug's use in combination with certain other classes of cardiac medications in patients with poor cardiac function is limited and may be uncertain.

Areas of Uncertainty and Research Gaps

The evidence landscape, while extensive, also highlights areas where additional research is needed. One key limitation is that results apply only to the populations studied, and research does not provide predictions for individual outcomes.

Regarding specific use patterns, long-term effects are not fully established for the management of chronic chest discomfort. Furthermore, for some specific high-dose regimens, the data supporting their use is primarily based on retrospective studies, which are not considered the highest quality of evidence. These research limitations frame the current boundaries of knowledge regarding this medication.

Common questions about Nifelat Retard (FAQ)

---

Q: What is the maximum daily dose I can take?

According to official product information, the maximum recommended daily dose for the extended-release formulation typically ranges from 90 mg to 120 mg once daily. Official labeling indicates the exact maximum dose depends on the product formulation and the condition being treated, which requires individualized assessment by a healthcare professional.

---

Q: What should I do if I forget to take my daily dose of Nifelat Retard?

Official patient information generally suggests that if a dose is missed, it should be taken as soon as it is remembered, unless it is close to the time for your next scheduled dose. If it is almost time for the next dose, it should be skipped. Official guidance emphasizes the importance of not taking double or extra doses to compensate for a missed one.

---

Q: Can I take Nifelat Retard with alcohol?

Official information indicates that alcohol may have an additive effect with Nifelat Retard in lowering blood pressure. This combination may increase the risk of side effects like headache, dizziness, or fainting, especially when treatment is initiated. It is important to discuss potential alcohol consumption with your healthcare provider.

---

Q: Is it safe for someone with severe liver problems to take Nifelat Retard?

Patients with impaired liver function require close medical supervision when taking Nifelat Retard, and regulatory documents state a lower starting dose may be necessary. Safety and pharmacokinetics (how the body processes the drug) have not been fully established in individuals with severe hepatic (liver) impairment. The drug is generally reserved for use with caution in these cases.

---

Q: What should I do if I take too much Nifelat Retard (overdose)?

Symptoms of taking too much Nifelat Retard may include extremely low blood pressure, a very slow or rapid heartbeat, dizziness, confusion, or severe nausea. If an overdose is suspected, it is critical that immediate medical assistance be sought, typically by contacting a Poison Control Center or Emergency Services.

---

Q: Can I crush the tablet and mix it with food or water to make it easier to swallow?

Regulatory information clearly specifies that the extended-release tablet is designed to be swallowed whole. It must not be crushed, split, or chewed, as doing so would disrupt the sustained-release mechanism, potentially causing the medicine to be released too quickly.

---

Q: Does Nifelat Retard affect my ability to drive or operate machinery?

Official warnings suggest that this medication can cause side effects like dizziness and fatigue, particularly when treatment begins. Individuals should avoid driving or operating hazardous machinery until they are aware of how the medication may affect their concentration and reaction time.

---

Q: Why do I sometimes see a shell of the tablet in my stool?

This is a normal and expected observation when taking this type of extended-release medication. The tablet is contained within a non-dissolving shell that is specifically designed to remain intact while slowly releasing the medicine into your system. After the medicine is absorbed by the body, the empty shell passes harmlessly into the stool.

How to Store and Dispose of Nifelat Retard

Nifelat Retard (Nifedipine extended-release tablets) must be stored under specific regulatory conditions to maintain the stability of the medication.

---

Storage Conditions

Requirement	Official Instruction
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C and do not freeze.
Protection	Keep the medicine out of the sight and reach of children. Must be protected from direct light, excess heat, and moisture.
Packaging	Keep in the original container and ensure the container is tightly closed at all times.

---

Disposal Instructions

Unused or expired Nifelat Retard must be disposed of properly. Patients are instructed to consult a healthcare professional or pharmacist regarding local waste disposal regulations. The medication should not be disposed of by flushing it down the toilet or placing it into the sewage system.